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The objective was to investigate survival of breast cancer patients at Mulago Hospital. A retrospective study of the medical records of
297 breast cancer patients referred to the combined breast clinic housed in the radiotherapy department between 1996 and 2000
was done. The female/male ratio was 24:1. The age range was 22–85 years, with a median of 45 years and peak age group of 30–39
years. Twenty-three percent had early disease (stages 0–IIb) and 26% had metastatic disease. Poorly differentiated was the most
common pathological grade (58%) followed by moderately differentiated (33%) and well-differentiated (9%) tumours. The
commonest pathological type encountered was ‘not otherwise specified’ (76%). Of all patients, 75% had surgery, 76% had
radiotherapy, 60% had hormonotherapy and 29% had chemotherapy. Thirty-six (12%) patients received all the four treatment
modalities. The 5-year survival probabilities (Kaplan–Meier) for early disease were 74 and 39% for advanced disease (P¼0.001).
The overall 5-year survival was 56%, which is lower than the rates in the South African blacks (64%) and North American whites
(82–88%).
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Cancer of the breast is a major health burden and the most
common cancer in women worldwide. It is among the most
common causes of cancer death in women in both high-resource
and low-resource settings, and is responsible for over 1 million of
the estimated 10 million neoplasms diagnosed worldwide each year
in both sexes (Ferlay et al, 2001). The incidence in developed
countries, for example, the United States and the United Kingdom,
is much higher, ranging between 50 and 100 per 100000 (Althuis
et al, 2005), and was responsible for about 375000 deaths in the
United States in 2000 (Bray et al, 2004).
Breast cancer is the third most common cancer in women in
Uganda after cancer of the cervix and Kaposi’s sarcoma (Parkin
et al, 1997). Breast cancer incidence in Uganda was 11:100000 in
1961 and had doubled to 22:100000 by 1995 (Wabinga et al, 2000).
The incidence in Zimbabwe is 20, in Gambia 4, in South Africa 70
(in whites) and 11 (in blacks) per 100000 (Vorobiof et al, 2001).
African women are diagnosed more often between 35 and 45
years, which is more than 15 years earlier than the women in
Europe and North America. The mortality rate in sub-Saharan
Africa is disproportionately high compared with the incident rate
(Fregene and Newman, 2005).
Five-year overall survival rate varies from 86% in Canada
(NCIC, 2006) to 88% in the United States (ACS, 2006), whereas it
was 80% in whites and 64% in blacks in South Africa (Vorobiof
et al, 2001).
The main objective of this study was to investigate the 5-year
overall survival of breast cancer patients treated at Mulago
Hospital, which is a national referral and tertiary centre.
PATIENTS AND METHODS
This was a retrospective study of 297 patients with histologically
diagnosed cancer of the breast referred to the combined multi-
disciplinary breast clinic, which is housed in the radiotherapy
department, from 1996 to 2000. An attempt to retrieve files of other
patients who might not have been referred to the combined breast
clinic was made but none was found. Patients’ files were manually
retrieved. All patients’ records, irrespective of their co-morbidities,
performance status, stage and treatment modalities, were included.
A review of their medical records was done in July 2006. The
following data were collected from their medical records:
(i) sex;
(ii) age of the patients at presentation;
(iii) stage at diagnosis (AJCC, 2002);
(iv) histological types;
(v) histological grades;
(vi) treatment modality given to the patient, for example, surgery,
radiotherapy, chemotherapy and hormonotherapy. Those
who did not receive any of these were also noted;
(vii) time in months when they died or got lost or if they were still
on follow-up.
Statistical analysis
The survival probabilities were worked out using the Kaplan–
Meier method of estimating the survival. All patients who received
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sany of the following modalities of treatment (surgery, chemotherapy,
radiotherapy and hormonotherapy) were analysed when estimat-
ing survival. Survival rate was taken as the proportion
of people diagnosed with a disease who live for a specific period
of time (ACS, 2006).
The 5-year cancer survival rate was therefore taken as the
proportion of cancer patients who were still alive, not necessarily
disease-free, 5 years after the diagnosis of cancer was made.
Twelve patients (4%) did not receive any of the above
treatments. They were not included in the calculation of the
survival rates.
A P-value of o0.05 was considered to denote statistical
significance. Histograms were used to present continuous variables
and tables used for categorical data.
TREATMENT POLICY
Patients were referred by surgeons to a combined multidisciplin-
ary clinic, which has been meeting every Friday for the past 13
years in the radiotherapy department. Final decisions on adjuvant
treatment were made during this meeting. We followed our
treatment guidelines, which were later published by The Uganda
Cancer Working Group (2003).
Surgical treatment was breast-conserving surgery, mastectomy
and auxiliary clearance for early disease. Toilet mastectomy was
performed in late disease stage when indicated. Combination
chemotherapeutic agents using cyclophosphamide, adriamycin and
5-fluorouracil (CAF) or cyclophosphamide, methotrexate and 5-
fluorouracil (CMF) were used. Radiotherapy was either radical (50–
66Gy) or palliative (8–30Gy) using a cobalt-60 teletherapy beam. A
dose of 50Gy in 25 fractions over a 5-week period was used after
mastectomy to the chest walls using two tangential fields. A similar
dose was delivered to the supraclavicular and auxiliary lymph node
regions when indicated. In cases of breast-conserving surgery, a
booster dose of 16Gy in eight fractions was given to the tumour bed.
In palliative situations, a dose range of 8Gy in single fraction to
30Gy in 10 fractions was given to either the breast or the metastatic
lesion(s). Hormonotherapy (tamoxifen) was offered to all patients
with a daily dose of 20mg for at least 5 years as oestrogen receptors
(ER), and progesterone receptors (PR) were not tested. Patients had
to buy the chemotherapy drugs and tamoxifen, as they were not
available in the hospital.
RESULTS
A total of 297 patients’ files were retrieved and all were analysed.
Basic demographics
Age The peak age group was 30–39 years. The median age was 45
years, mode 50 years and mean 47 years with a range of 22–85
years. Figure 1 shows the age distribution of the patients.
Sex There were 285 (96%) female patients and 12 (4%) male
patients. The male/female ratio was 1:24.
Stage The stage was established in 243 (82%) patients. Stage III
was the peak stage at presentation with 51% of all patients; 26.3%
of the patients were metastatic at presentation. Only 23% were
early cancers (stages 0–IIb). Figure 2 shows the stage of the
patients at presentation.
Histological types Histological types were available for 122 out of
297 (41%) patients. The most common histological type was
‘infiltrating ductal carcinoma – not otherwise specified’ making up
76% of the patients. Table 1 shows the histological types of
patients.
Histological grades Histological grades were available for 83 out
of 297 (28%) patients. Of these, 58% were poorly differentiated.
The histological grades are shown in Figure 3.
Treatment Two hundred and twenty-two (75%) patients received
surgery (mastectomy and auxiliary clearance, toilet mastectomy
and breast conservative surgery).
A total of 227 (76%) patients received external radiotherapy with
a cobalt-60 beam. All the 15 patients (5%) who underwent breast-
conserving surgery received a total dose of 66Gy to the tumour
bed with good cosmetic results. We did not have any incidence of
salvage surgery after this treatment. Palliative radiotherapy was
given to the 26% who had metastatic disease. This palliative
treatment resulted in good response regarding pain relief and
tumour regression in 80% of the patients treated. Spinal cord
compression was the most common problem in the patients who
presented with metastatic disease.
Seventy patients did not receive any of the radiation therapy. In
54 patients, the staging documentation was unclear from the
records (Figure 2). These patients were part of the 70 patients who
did not receive radiotherapy.
Chemotherapy
Eighty-seven patients (29%) completed the six cycles of (CAF)
chemotherapy as reflected in Figure 4. Thirty-one patients
discontinued therapy after one or two cycles and these patients
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Figure 1 Age distributions.
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Figure 2 Stage at presentations.
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swere not included in the histogram showing treatment modalities
in Figure 4. They were, however, included in the calculations for
the survival curves, as they received other treatments such as
surgery and radiotherapy. One hundred and twenty patients never
received chemotherapy, although they needed it according to our
management guidelines. They, however, received other treatment
modalities.
Figure 4 shows those who received the different treatment
modalities.
In summary, 285 had some form of treatment; of these, 227
had radiotherapy, 222 had surgery, 177 had tamoxifen and 87 had
chemotherapy.
Eighty-five patients died. Of the 285 patients who were eligible
for analysis, only 79 (28%) were still being followed up at the end
of the 5-year period.
Five-year overall survival
The 2-year survival probabilities (Kaplan–Meier) were 94% for
early disease stage and 56% for advanced disease stage (P¼0.002),
whereas those for 5-year survival were 74% for early disease stage
and 39% for advanced disease stage (P¼0.001). The overall 5-year
survival was 56%. Figure 5 shows the percentage survival rates for
early disease, advanced disease and for all patients who received
some form of treatment.
DISCUSSION
Five-year overall survival
Our 5-year survival rate was 74% for early disease stage and 39%
for advanced disease stage. This is low compared with the
American Cancer Society (2006) data , which were 97% for
localised disease and over 47% for the late disease stage. Our
5-year overall survival rate, which was 56%, also compares
unfavourably with those of the United States and Canada, which
are 88 and 86%, respectively (ACS, 2006; NCIC, 2006). It is also low
compared with the South African whites whose 5-year survival
was 80%, but it is comparable with the survival in blacks, which
was only 64% (Vorobiof et al, 2001).
These low survival rates may not be surprising considering that
patients are disadvantaged regarding almost all the known
prognostic factors, such as stage at diagnosis, histological grade
and aggressiveness of the disease, availability and accessibility to
appropriate treatment modalities and probably age at diagnosis.
Stage at presentation
Bray et al (2004), while emphasising that prognosis is heavily
dependent on stage of disease at presentation, points out that in
the Surveillance, Epidemiology, and End Results (SEER) registries
in the United States, 5-year survival for localised cases in 1994 was
Table 1 Histological types
Type Percent
IDC (not otherwise specified) 76
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Schirrous 7
Others 5
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Figure 3 Pathological grades.
Surgery
Radiotherapy
Hormonotherapy
Chemotherapy
0
50
100
150
200
250
N
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
Type of treatment
Received Not received
Figure 4 Treatment modalities.
0
20
40
60
80
100
120
02 04 06 0 8 0
Period (months)
P
e
r
c
e
n
t
a
g
e
Early Overall Advanced
Figure 5 Survival probabilities (Kaplan–Meier).
Breast cancer outcomes
A Gakwaya et al
65
British Journal of Cancer (2008) 99(1), 63–67 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sabout 97% but was only about 25% for cases with metastatic
disease.
Twenty-six percent of patients presented with metastatic
disease. Even in the high-resource settings, treatment outcome is
poor in metastatic disease. When metastatic disease is combined
with stage III disease, they contributed more than 77% of all
patients. This is late presentation compared with only 26% in
Beirut (Saghir et al, 2006). In the United States, more than 22% of
the patients present with carcinoma in situ disease. This is related
to the rise in mammography-detected incidental cases as a result of
the intensification of breast screening (Bray et al, 2004; ACS, 2006).
There is, however, no screening programme in Uganda.
When one compares our survival rates with data from Nigeria,
South Africa and Zimbabwe, it is noted that black Africans have
three features in common: late stage in seeking treatment, lower
age at peak incidence and severe tumour burden that takes a more
aggressive course and consequently lower survival rates (Ihekwaba,
1992; Clayton and Byrd, 1993; Muguti, 1993; Moormeir, 1996;
Ijaduola and Smith, 1998). In all these series, stages III–IV disease
made up between 75 and 85% of all patients seen. It is, therefore,
not surprising that Muguti (1993) reports a median survival of
only 12 weeks in the 25 patients who were followed up to death.
We think that there are many socioeconomic factors that
contribute to the late presentation of patients in Uganda. They
include a low doctor/population ratio of 1:18750, a per capita
income that is only USD 400 per annum, poor infrastructure, a low
per capita health expenditure of $12 per annum, low literacy rate of
49% among females, stigma and inappropriate health-seeking
behaviour where a person only goes to a health facility when he/
she is critically sick.
Histological grade and more aggressive disease
Fifty-seven percent of these tumours were poorly differentiated.
This shows that a large proportion of patients had a more
aggressive type of disease. This grade, with other parameters
(tumour size and lymph node stage) remaining the same, has poor
prognosis predictors/factors (D’Eredita et al, 2001). Although it is
known that large tumours tend to be high grade and most tumours
were of stage III, this percentage of poorly differentiated tumours
must have contributed to the low 5-year survival rates. We were
not able to compare this high proportion of poorly differentiated
tumours with other series from Africa, as we did not find any
report on pathologic grades.
A racial disparity in the progression of breast cancer has already
been observed. This points to possible differences in the aetiology
or in the genetic make-up of the two faces (Ochieng et al, 1997).
This more aggressive nature of breast cancer in blacks can be
further attributed to the fact that most tumours diagnosed are
ER-negative (Chen et al, 1994; Gapsfar et al, 1996; Thomson et al,
2001). Oestrogen receptor-negative tumours tend to be more
poorly differentiated and may have a shorter doubling time in vivo
(Garret et al, 1993; Elias et al, 1994; Elledge et al, 1994). This may
be an additional factor explaining why patients present with more
advanced disease. We were not able to test for hormonal receptor
status owing to limited resources and cannot confirm this
correlation.
Of the total tumours, 76% was ‘infiltrating ductal carcinoma, not
otherwise specified’ (IDC, NOS). This agrees with other literature
(Chao et al, 1999), but it is higher than the 49% reported by
Ihekwaba (1992) from Nigeria.
Treatment
In high-resource to medium-resource settings, advances in breast
cancer therapy in recent years have made a considerable
contribution to improved survival and the subsequent reduction
or stabilisation of breast cancer death rates. A most likely
contributory factor to the decline, as noted in the United Kingdom,
has been the establishment of treatment protocols, improved
chemotherapeutic options or better therapeutic guidelines. Specific
structural changes that have embraced specialisation of breast
cancer care (such as, centralised treatment, adjustments in
clinician workload and use of multidisciplinary teams) have been
shown to improve outcome (Bray et al, 2004).
A combined multidisciplinary team has been meeting every
week in Mulago hospital for the past 13 years and has been
responsible for the production of the breast cancer guidelines for
Uganda (The Uganda Cancer Working Group, 2003). We
endeavoured to treat all the patients according to these guidelines
despite resource limitations and difficulties with patient follow-up.
Surgery and radiotherapy were done according to our guidelines
and these modalities were probably optimised. Of total patients,
75% underwent surgery. Of these, 58% had mastectomy plus
auxiliary clearance (modified radical mastectomy), 35% had toilet
mastectomy and 7% had conservative breast surgery. The
percentage of patients who received breast-conserving surgery
could have been higher, because up to 23% had stages 0–II
disease. The knowledge that breast conservation is possible may
have a multiplier effect on early presentations, as it encourages
patients to come even earlier.
Fregene and Newman (2005) stated that treatment of breast
cancer in sub-Saharan Africa is largely limited to surgery because
of limited access to adjuvant therapy. Mastectomy is, therefore, the
treatment of choice for the majority of cases. Another study
(Muguti, 1993) cited the expense of travelling long distances to a
hospital as the primary reason for patients having to restrict their
therapeutic options. Both of these explanations may have
contributed to the low percentage (29%) of patients who received
chemotherapy.
Despite this, 76% of all patients received radiotherapy. This was
radical for stages 0–III disease with an attempt to improve their
survival, but only palliative treatment was given to the 26% who
had metastatic disease.
Only 29% had chemotherapy (CAF). Even this traditional
chemotherapy is too expensive for our population. A course of
treatment costs about USD 250.
Although all the patients were given a prescription for
tamoxifen, only 60% of them got this potentially useful treatment.
It was not available in the hospital and the patients had to buy the
medicine. Some could not afford this drug, which in developed
countries is taken as a cheap drug and costs only about USD 4 per
month in the open market.
A formula should, therefore, be found to improve access to these
treatments. The new chemotherapies are not available.
Age
The peak age in our series was 30–39 years, which is a young age
group compared with 60–69 years in the United States (Pathak
et al, 2000). The mean age at presentation of 47 years is
comparable with the work done by Saghir et al (2006) in Beirut
and Fregene and Newman (2005) in the United States. Young age
at diagnosis of breast cancer has been reported in many studies
from the United States and Europe to be an independent predictor
of worse survival (Saghir et al, 2006). Breast cancers in Uganda
occur in a younger population than those in the Western countries
(Pathak et al, 2000) but are similar to the Nigerian and
Zimbabwean situations (Ihekwaba, 1992; Muguti, 1993; Ikpatt
et al, 2002). Our results show that 54% of all patients were below 50
years of age, whereas Swanson and Lin (1994) reported age
incidence in the United States of less than 23% in the same age
bracket. This means that when Uganda is planning strategies for
detection, diagnosis, treatment and research, it should address the
young. Ochieng et al (1997) and Garrett et al (1993)recommended
that a cause for the age disparity should be looked for. They
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spostulated a possible genetic or environmental cause. It is,
however, possible that our data may not reflect a true increased
incidence in the young women, as life expectancy is low in Uganda
and only 4.2% of all women are above 50 years (UBOS, 2005).
Despite this, we still think that our peak age of 30–39 years may be
the youngest reported in literature.
Sex
Of all cancer patients, 4% were male patients, which compares with
Tanzania’s 6.7% (Amir et al, 1996). These figures are very high
compared with figures in Europe and the United States, where
rates of less than 1% are quoted (Jonasson et al, 1996; Hill et al,
2005; ACS, 2006; NCIC, 2006). What causes the high rates of male
breast cancer in Africa is still unknown. The absolute numbers of
male breast cancers were too low for us to ascertain whether the
behaviour of these tumours differed from that occurring in the
females.
Patient follow-up
This is difficult in our setting and may also contribute to the low
survival rates, as some patients who may be taken as dead may still
be alive. Although the Kaplan–Meier method makes allowance for
these patients, still 46% of all patients lost in a 5-year period
constitute a large percentage. The socioeconomic factors
mentioned above compound the problem.
CONCLUSIONS AND RECOMMENDATIONS
In conclusion, our study shows that the peak age was 30–39 years,
26% of the patients presented with metastatic disease, 58% were
aggressive poorly differentiated tumours and that the overall
5-year survival rate was only 56%.
We recommend that a more detailed study to characterise breast
cancer in the young African woman and a ‘National Cancer
Control Programme’ be initiated to specifically improve access to
diagnostic and therapeutic facilities in Uganda.
REFERENCES
Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA (2005) Global
trends in breast cancer incidence and mortality 1973–1997. Int
J Epidemiol 34(2): 405–412
American Cancer Society (ACS) (2006) Cancer facts and figures.
www.acs.org
American Joint Committee on Cancer (2002) Chapter on breast. In AJCC
Cancer Staging Manual, Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG, Morrow M (eds) AJCC 6th edn, pp 221–240.
Lippincott-Raven: Philadelphia
Amir H, Makwaya CK, Moshiro C, Kwesigabo G (1996) Carcinoma of the
male breast: a sexually transmitted disease. East Afr Med J 73: 187–190
Bray F, McCarron P, Parkin MD (2004) The changing global patterns of
female breast cancer incidence and mortality. Breast Cancer Res 6: 229–239
Chao C, Perez CA, Brandy LW (1999) Breast: Pathological Classification in
Radiation Oncology Management Decisions 2nd edn, pp 349. Lippincott
Williams & Wilkins: Philadelphia
Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, Austine D (1994)
Histological characteristics of breast carcinoma in blacks and whites.
Cancer Epidemiol 3: 127–135
Clayton LA, Byrd WM (1993) The African American cancer crisis. The
problem. J Health Care 4: 83–101
D’Eredita GD, Giardina C, Marlellota M (2001) Prognostic factors in breast
cancer: the predictive value of the Nottingham prognosis index in
patients with a long term follow up that were treated in a single
institution. Eur J Cancer 37: 591–596
Elias EG, Suter CM, Brown SD, Buda BS, Vachon DA (1994) Survival
differences between black and white women with breast cancer. J Surg
Oncol 55: 37–41
Elledge RM, Clark GM, Chammess GC, Osborne GK (1994) Tumor biologic
factors and breast cancer prognosis among white, Hispanic and black
women in the United States. J Natl Cancer Inst 86: 705–712
Ferlay J, Bray F, Pisani P, Parkin DM (2001) Cancer Incidence, Mortality
and Prevalence Worldwide GLOBOCAN 2000 IARC CancerBase No. 5
[10]. IARC: Lyon, France
Fregene A, Newman LA (2005) Breast cancer in sub-Saharan Africa: how
does it relate to breast cancer in African-American women? Cancer
103(8): 1540–1550
Gapsfar SM, Dupuis J, Gann P, Celia S, Winchester DP (1996) Hormone
receptor status of breast tumors in black. Hispanic and non-Hispanic
white women. Cancer 77: 1465–1467
Garrett PA, Hulka BS, Kim YL, Farber RA (1993) HRA S proto-oncogene
polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 2:
131–138
Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ (2005) Comparison of male
and female breast cancer incidence trends, tumor characteristics, and
survival. Ann Epidemiol 15(10): 773–780
Ihekwaba FN (1992) Breast cancer in Nigerian women. Br J Surg 79(8):
771–775
Ijaduola TG, Smith EB (1998) Pattern of breast cancer among white-
American, African-American, and nonimmigrant West-African women.
J Natl Med Assoc 90(9): 547–551
Ikpatt OF, Kuopio T, Collan Y (2002) Proliferation in African breast cancer:
biology and prognostication in Nigerian breast cancer material. Mod
Pathol 15(8): 783–789
Jonasson JG, Agnarsson BA, Thorlacius S, Eyfjord JE, Tulinius H (1996)
Male breast cancer in Iceland. Int J Cancer 65: 446–449
Moormeir J (1996) Breast Cancer in black women. Ann Intern Med 124:
897–905
Muguti GI (1993) Experience with breast cancer in Zimbabwe. J R Coll Surg
Edinb 38(2): 75–78
National Cancer Institute of Canada (NCIC) (2006) Canadian cancer
statistics 2006. NCIC, www.ncic.cancer.ca
Ochieng J, Warfield PBS, Johnson KN (1997) Establishment of breast cell
cultures and lines from peoples of African origin. Am J Obstet Gynaecol
176: 5240–5245
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (1997) Cancer
Incidence in Five Continents. VIII. IARC, Lyon: IARC Scientific
Publications
Pathak DR, Osuch JR, He J (2000) Breast carcinoma etiology: current
knowledge and new insights into the effects of reproductive and
hormonal risk factors in black and white populations. Cancer 88(5
suppl): 1230–1238
Saghir NE, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB,
Shamseddine AI (2006) Effects of young age at presentation on survival
in breast cancer. BMC Cancer 6: 194
Swanson GM, Lin CS (1994) Survival patterns among younger women with
breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer
Inst Monogr 16: 69–77
The Uganda Cancer Working Group (2003) Breast cancer guidelines for
Uganda (practice points). Afr Health Sci 3(1): 47–52
Thomson CS, Hole DJ, Twelves CJ, Brewser DH, Black RJ (2001) Prognostic
factors in women with breast cancer: distribution by socio-economic
status and effect on differences in survival. J Epidemiol Community
Health 55: 308–315
Uganda Bureau of Statistics (UBOS) (2005) Uganda Bureau of Statistics.
Final report of the 2002 Population Census of Uganda; www.ubos.org
Vorobiof DA, Sitas F, Vorobiof G (2001) Breast cancer incidence in South
Africa. J Clin Oncol 19(No 18S): 125s–127s
Wabinga HR, Parkin DM, Wabwire-Mangeni F, Nambooze S (2000) Trends
in cancer incidence in Kyadondo county, Uganda, 1960–1997.
Br J Cancer 82: 1585–1592
Breast cancer outcomes
A Gakwaya et al
67
British Journal of Cancer (2008) 99(1), 63–67 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s